A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

Prior treatment

• Patients who have received a stem cell transplantation within 5 years
• Use of investigational agents within 8 weeks or 5 half-lives of study drug administration (whichever is larger)
• Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone (or anti-inflammatory equivalent) within 72 hours of start of study drug administration
• Received a calcineurin inhibitor (eg, tacrolimus, cyclosporine) within 30 days of study drug administration
• Received cyclophosphamide, rituximab, obinutuzumab, other anti-CD20 or B cell-depleting agents, or proteasome inhibitors or anti-CD38 therapies (eg, isatuximab, daratumumab) within 12 months of study drug administration
• Prior treatment with any anti-BCMA antibody (including antibody drug conjugate or bsAb) or BCMA-directed CAR-T cell therapy, as described in the protocol
• Has received a COVID-19 vaccination, as described in the protocol
  • Note: Other protocol defined inclusion / exclusion criteria apply

Other illness

• Current or active malignancy not in remission for at least 1 year
• Central nervous system (CNS) pathology or history of CNS neurodegenerative or movement disorders

Lab values

• Total plasma IgG \<300 mg/dL at screening

Other

• Patients who have had their spleen removed, including patients with functional asplenia

• Has Chronic Kidney Disease (CKD) requiring hemodialysis, and awaiting kidney transplant on the United Network for Organ Sharing (UNOS), with a cPRA ≥99.9%, or those with a cPRA \>98% (98.1% to 99.8%) who have spent 5 years or longer on the waitlist, as defined in the protocol
• Adequate hematologic and adequate hepatic function as defined in the protocol
• Willing and able to comply with clinic visits and study-related procedures